Summit Therapeutics (SUMM)
SUMM Share PerformanceMore
|52 week high||269.75 11/09/17|
|52 week low||138.25 03/01/17|
|52 week change||15.00 (8.57%)|
|4 week volume||581,732 22/09/17|
Media for (SUMM)
Presenter: Mark Wilcox
Presenter: Mark Wilcox
- 1 of 2
Latest News« previous» nextMore
13/10/2017 - 09:10 RNS
Summit Therapeutics plc: Holding(s) in Company TR-1: S tandard form for notification of major holdings 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Summit Therapeutics PLC Sedol BN40HZ0 1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) Non-UK issuer 2. Rea...
09/10/2017 - 13:11 StockMarketWire
Summit has announced that at ID Week 2017, it presented further positive gut microbiome data of ridinilazole from its ex...
09/10/2017 - 12:00 RNS
Summit Highlights Microbiome Preservation During Ridinilazole Treatment at ID Week 2017 Summit Therapeutics plc ('Summit' or the 'Company') SUMMIT HIGHLIGHTS MICROBIOME PRESERVATION DURING RIDINILAZOLE TREATMENT IN EXPLORATORY PHASE 2 CLINICAL TRIAL AT ID WEEK 2017 Oxford, UK, 9 October 2017 - Summit Ther...
05/10/2017 - 16:25 RNS
Summit Therapeutics plc: Exercise of Options Summit Therapeutics plc ("Summit" or the "Company") EXERCISE OF SHARE OPTIONS Oxford, UK, 5 October 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, announce...
04/10/2017 - 13:03 StockMarketWire
Summit Therapeutics has confirmed that the Company and its collaborators will be presenting at the 22nd International C...
04/10/2017 - 12:00 RNS
Summit Highlights DMD Biomarker Validation Data at 22nd WMS Congress Summit Therapeutics plc ('Summit', or 'the Company') SUMMIT HIGHLIGHTS DMD BIOMARKER VALIDATION DATA AND PHASE 2 CLINICAL TRIAL BASELINE CHARACTERISTICS IN PRESENTATIONS AT 22NDWMS CONGRESS Oxford, UK, 4 October 2017 - Summit Th...
03/10/2017 - 11:15 RNS
Summit Therapeutics plc: Exercise of Options Summit Therapeutics plc ("Summit" or the "Company") EXERCISE OF SHARE OPTIONS Oxford, UK, 3 October 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, announce...
02/10/2017 - 13:29 StockMarketWire
Summit Therapeutics has confirmed that the Company will host an R&D Day featuring presentations from experts in qu...
|Dividend yield||0 %|
Latest discussion posts More
“So after todays press release all of the gain made following the previous press release has been wiped out in one foul swoop. It seems every time we get a decent rise in the ...”▼
“ps valid points raised. Sold these in two lots, 247 and 177 as could only see drift until 2018. C diff drug trying to break into an established market, always difficult ...”▼
“The article referenced on Interactive Investor states that Summit Therapeutics has 2 potential treatments "both well down the road to becoming proven and commercial products". ...”▼
Codes & Symbols
|Symbols||SUMM, LSE:SUMM, SUMM.L, SUMM:LN, LON:SUMM, XLON:SUMM|